rupiya.io
⠋Loading...
0%
❯ Parsing revenue segments...
Jubilant Pharmova Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Jubilant Pharmova Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹5,762 Cr | ₹5,751 Cr | ₹5,749 Cr | |||||||||
| Expenses | ₹4,763 Cr | ₹5,141 Cr | ₹4,493 Cr | |||||||||
| Operating Profit | ₹999 Cr | ₹610 Cr | ₹1,256 Cr | |||||||||
| OPM % | 17.0% | 11.0% | 22.0% | |||||||||
| Other Income | ₹-173 Cr | ₹86 Cr | ₹4 Cr | |||||||||
| Depreciation | ₹281 Cr | ₹288 Cr | ₹347 Cr | |||||||||
| Interest | ₹337 Cr | ₹368 Cr | ₹371 Cr | |||||||||
| Profit Before Tax | ₹207 Cr | ₹40 Cr | ₹542 Cr | |||||||||
| Tax | ₹207 Cr | ₹40 Cr | ₹542 Cr | |||||||||
| Net Profit | ₹138 Cr | ₹-40 Cr | ₹387 Cr | |||||||||
| EPS (₹) | 6.8 | -3.6 | 24.6 | |||||||||
| Dividend Payout % | 43% | -83% | 12% |
Register free to see 9 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,552 Cr | ₹1,678 Cr | ₹1,587 Cr | ₹1,680 Cr | ||||||||
| Expenses | ₹1,408 Cr | ₹1,459 Cr | ₹1,419 Cr | ₹1,438 Cr | ||||||||
| Operating Profit | ₹144 Cr | ₹219 Cr | ₹168 Cr | ₹242 Cr | ||||||||
| OPM % | 9.0% | 13.0% | 11.0% | 14.0% | ||||||||
| Depreciation | ₹94 Cr | ₹271 Cr | ₹90 Cr | ₹97 Cr | ||||||||
| Interest | ₹51 Cr | ₹56 Cr | ₹62 Cr | ₹66 Cr | ||||||||
| Net Profit | ₹-16 Cr | ₹-100 Cr | ₹6 Cr | ₹62 Cr | ||||||||
| EPS (₹) | -1.0 | -6.2 | 0.4 | 3.9 |
Register free to see 8 more quarters.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹15 Cr | ₹16 Cr | ₹16 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹2,611 Cr | ₹2,438 Cr | ₹2,951 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹4,395 Cr | ₹4,793 Cr | ₹4,493 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹1,842 Cr | ₹1,372 Cr | ₹1,280 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹8,864 Cr | ₹8,619 Cr | ₹8,740 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹5,099 Cr | ₹4,911 Cr | ₹5,104 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹34 Cr | ₹40 Cr | ₹85 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹3,259 Cr | ₹3,071 Cr | ₹2,939 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹8,864 Cr | ₹8,619 Cr | ₹8,740 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 9 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹772 Cr | ₹-164 Cr | ₹-414 Cr | — |
| Mar 2016 | ₹783 Cr | ₹-362 Cr | ₹-503 Cr | — |
| Mar 2017 | ₹1,099 Cr | ₹-309 Cr | ₹-843 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 9 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.